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During the past decade, liver transplantation advanced rap-
idly to the forefront of therapies available for patients with 
end-stage liver disease and has had a dramatic impact on the 
practice of hepatology. Advances in immunosuppression, re-
finement of surgical technique, new methods of organ pro-
curement and preservation, improved peri operative patient 
care, new agents for prophylaxis and treatment of oppor-
tunistic infection, and wider public and professional accept-
ance of voluntary cadaveric organ donation have all contrib-
uted significantly to the progress in this field. 
Figure 43-1 demonstrates the linear increase in case ex-
perience in Europe and the United States during the last 5 
years of the 1980s. Since October 1, 1987, a national liver 
transplant registry has been maintained by the United Net-
work for Organ Sharing, which operates under federal con-
tract as the national organ sharing and procurement network. 
Through December 1989, 66 transplant centers had reported 
4193 liver transplantations in 3610 patients (Fig. 43-2). Dur-
ing the same period, Western European centers reported to 
the European Liver Transplant Registry in Paris 2964 liver 
transplantations in 2706 patients+! (Fig. 43-3). 
Indications for Liver Transplantation 
Liver transplantation is performed for many diseases that lead 
to irreversible acute and chronic liver failure, for which no 
reasonable medical or surgical alternative therapy exists. In 
both Europe and the United States, the leading indications 
for liver replacement are cirrhosis, cholestatic liver disease 
(primary biliary cirrhosis [PBC], sclerosing cholangitis, bili-
ary atresia), inborn errors of metabolism, fulminant hepatic 
failure, and neoplasms (Fig. 43-4). Among the patients with 
cirrhosis, posthepatitic and alcoholic cirrhosis are the most 
common types for which liver transplantation is performed 
(Fig. 43-5). Patient survival rates after liver transplantation in 
the United States and Europe for common indications are 
summarized in Table 43-1. 
PARENCHYMAL UVER DISEASE 
P08tnecrotic Cirrho8is 
Patient survival rates after liver transplantation for post-
necrotic cirrhosis, excluding hepatitis B surface antigen 
(HBsAg)-positive patients, are 73% to 75% at 1 year and 67% 
1210 
to 73% at 2 years (see Table 43-1). The hepatitis C virus 
(HeY), a ribonucleic acid virus recently cloned by Choo and 
associates, 19 is believed to be the agent responsible for most 
cases of transfusion-related non-A, non-B hepatitis. The pre-
cise incidence of posttransplantation HeY-related hepatitis is 
not known, but preliminary studies from the Mayo Clinic 
suggest that Hey is an important cause of posttransplanta-
tion chronic hepatitis and that a significant p.roportion of 
cases represent recurrent HeY-related disease.
' 
9 
Reinfection after liver transplantation in HBsAg-positive 
patients is common, and overall patient and graft survival 
rates have not been as high as for other forms of cirrhosis. 
Although many patients enjoy a prolonged period of rehabil-
itation after liver transplantation for hepatitis B virus (HBY)-
related cirrhosis, most retain the carrier state, and there is a 
high reinfection rate. 28.37.65.110.117.127 At the University of Pitts-
burgh, 1- and 2-year patient survival rates for postnecrotic 
cirrhosis in HBsAg-negative patients are 76% and 73%, re-
spectively, but the same rates for HBsAg-positive patients are 
58.8% and 48.6%, respectivelyY Registry survival rates in 
Europe (68% at 2 years) have been better than survival rates 
reported in the United States (43% at 2 years) in HBsAg-
positive patients for reasons that are not known but that may 
relate to differences in strategies used to alter the incidence 
and course of HBY infection. 
Several approaches have been reported to alter the course 
of HBY reinfection of a liver allograft, including active im-
munization with hepatitis vaccine, passive immunization 
with hyperimmune globulin, and immunomodulation with 
a_interferon.15.37.81,99.IZ9.149 In all these reports, there was evi-
dence that perioperative and postoperative therapy with hy-
perimmune globulin may delay the reappearance and, in 
some cases, provide long-term clearance of HBsAg. Further 
trials of long-term passive immunoprophylaxis appear war-
ranted. On the other hand, treatment with a-interferon, 
which has shown some promise in altering the course of 
HBY infection in the nontransplantation situation, has yet to 
show any significant promise in transplant recipients. 37.122.149 
Alcoholic Cirrho8i8 
Alcoholic cirrhosis is the most common cause of chronic 
liver disease in Western society. Because of the hazards as-
sociated with surgery in such patients and a high risk of re-
cidivism, Laennec's cirrhosis had been considered a contrain-
dication to liver transplantation. In fact, recent experience 
has shown that patient survival rates after liver transplanta-
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FIGURE 43.1 Liver transplantations performed per year in the United States and Europe, 1985 to 
1989. 
for alcoholic cirrhosis are comparable with patient sur-
rates after liver transplantation for postnecrotic cirrhosis 
cholestatic liver diseasell.63.140 (see Table 43-1). 
Actual rates of recidivism are difficult to determine, since 
. denial is common but not always truthful and obiec-
jKlaillvlv~y is not always available. Recidivism rates are 
than those published so far, but it is clear 
the patients at greatest risk are those who are actively 
nnt,lrir,rr just before transplantation. It is difficult to justify 
ing a prolonged period of abstinence before trans-
n, since manv patients are too ill to wait. The ex-
patient survival rates that have been achieved must 
matched by similar improvements in methods of re-
and behavior modification. 
43.2 Liver transplantation in the United 
October 1987 to December 1989. Numbers in 
face are transplantations performed in each state; 
in italics are transplant centers in each state. A 
4193 transplantations were performed in 3610 
in 66 centers. 
CHOLESTATIC LIVER DISEASE 
Sclerosing Cholangitis 
Cholestatic liver diseases, including sclerosing cholangitis, 
PBC, and biliary atresia, are among the best established in· 
dications for liver transplantation, but issues remain concern-
ing patient selection, alternative surgical procedures, and 
timing of transplantation. 
Primary sclerosing cholangitis (PSC) is a progressive dis-
ease with a substantial morbidity and mortality, even when it 
is detected in asvmptomatic patients. 116 Although only a 
small percentage of patients with inHammatory bowel disease 
eventually develop PSC, as many as 70% of cases of scleros-
ing cholangitis have been associated with inflammatory 
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FIGURE 43·3 Liver transplantation in Europe, October 1987 to 
December 1989. Numbers in normal face are transplantations per-
formed in each state; numbers in italics are transplant centers in 
each state. A total 2964 grafts were performed in 2706 patients and 
67 centers in the registry as of December 1989. 
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bowel disease. 165 The disease is associated with an increased 
risk of cholangiocarcinoma. In patients with ulcerative coli-
tis, there is also an increased risk of adenocarcinoma of the 
colon. Thus, the evaluation of patients with PSC should in-
clude a complete evaluation of the biliary tree and gastroin-
testinal tract. Multiple percutaneous or endoscopic brushings 
of the biliary tree are recommended. A negative brushing on 
one examination is insufficient, in our experience, to exclude 
the presence of biliary tract tumor. 
Conventional biliary tract reconstructive surgery is advo-
cated for cases that have not progressed to persistent jaundice, 
refractory cholangitis, secondary biliary cirrhosis, and portal 
hypertension, especially for patients in whom obstructive dis-
ease is limited to the hepatic duct bifurcation or extrahepatic 
biliary tree. 16,85 Only a minority of patients may qualify for 
such surgery, given the usual distribution of the disease and 
its progressive nature. In a series of 178 cases recently re-
viewed by the Lahey Clinic, 71 % of patients had intrahepatic 
or diffuse disease. Although they reported some benefit of 
biliary surgery in 75% of cases, subsequent operations were 
associated with a higher morbidity and mortality, 91 Involve-
ment of the extrahepatic bile ducts alone may be more com-
mon in patients without associated inflammatory bowel dis-
ease. 121 
Survival after liver transplantation for PSC in patients free 
of cancer is comparable with survival after liver transplanta-
tion for other cholestatic liver diseases and for postnecrotic 
cirrhosis (see Table 43-1). Given the excellent results that are 
attainable with this form of surgery, 80,90 we recommend con-
servative use of conventional biliary tract reconstructions, ex-
cept in those patients without cirrhosis and portal hyperten-
sion and with distribution of disease that is easily approached, 
Reoperation should be avoided. Many patients who require 
biliary tract decompression but who probably will require 
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FIGURE 434 Primary indications for liver transplantation in the United States and Europe. 
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FIGURE 43.5 Causes of postnecrotic cirrhosis in patients receiving liver transplants in the United 
States and in Europe. 
TABLE 43.1 Patient Suroival Rates After Liver Tramplantation in Europe and the 
United States 
Patient Suroival (%) 
Indication RegUtry* Patients 6 rno 12 rna 18 rno 24 rno 
Biliary atresia ELTR 235 70 68 68 68 
UNOS 413 81 78 75 75 
Sclerosing cholangitis ELTR 102 79 76 73 73 
UNOS 319 85 81 79 76 
Primary biliary cirrhosis ELTR 347 78 75 74 73 
UNOS 398 84 81 78 76 
Fulminant hepatic failure ELTR 353 61 59 57 56 
UNOS 385 65 61 58 58 
Postnecrotic cirrhosis' ELTR 347 78 75 74 73 
UNOS 1536 76 73 69 67 
HBsAg-positive ELTR 164 89 75 72 68 
UNOS 204 72 64 55 43 
Alcoholic cirrhosis ELTR 199 73 69 67 67 
UNOS 432 78 76 76 71 
Budd-Chiari syndrome ELTR 38 85 61 61 61 
UNOS 40 87 71 
Hepatoma ELTR 279 67 58 45 45 
UNOS 81 77 67 61 
ELTR, European Liver Transplant Registry; UNOS, United Network for Organ Sharing; HBsAg, hepatitis B surface an-
tigen. 
"Based on actuarial patient survival data from the ELTR and the UNOS for the period October 1987 to December 1989. 
ELTR data provided courtesy of Professor Henri Bismuth. 
'Except patients positive for HBsAg. 
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transplantation can be managed by percutaneous stenting un-
til livers can be found. 
The incidence of cholangiocarcinoma in patients with 
PSC has been similar, in our experience, in patients with and 
without associated inflammatory bowel disease. 121 Results af-
ter liver transplantation for sclerosing cholangitis in patients 
with coexisting cholangiocarcinoma have been disappoint-
ing. In a series of 10 patients, 6 died of recurrent cancer, 
usually within I year of transplantation. 142 Only three pa-
tients were alive at 4 months to more than 2 years at the time 
of the report. The role of aggressive adjuvant radiotherapy 
remains to be established. 
Prior colectomy and ileostomy for ulcerative colitis were 
once considered contraindications to liver transplantation, 
but this is no longer true. In recent experience, these patients 
have fared well and most have not proved to be difficult tech-
nical cases. Patients in whom prior colectomy has not been 
performed may have persistent disease after transplantation, 
despite immunosuppression with regimens that usually in-
clude steroids. Careful surveillance for the development of 
adenocarcinoma is important and may necessitate subse-
quent colectomy. In a series of 36 patients given liver trans-
plants for sclerosing cholangitis associated with ulcerative co-
litis, 2 patients died of recurrent cholangiocarcinoma that 
was not appreciated before transplantation and 2 patients 
were found to have adenocarcinoma of the colon 11 and 21 
months after transplantation. 60 
Primary Biliary Cirrhosis 
Primary biliary cirrhosis has been one of the most common 
and most successful indications for liver transplantation. Al-
though the disease has a higher prevalence in older patients, 
especially women, a number of compensating factors may 
contribute to the good outcome after liver transplantation. H 
Most patients have had little, if any, upper abdominal surgery 
(prior cholecystectomy is the most common), and the large 
liver usually found in patients with PBG is easy to remove 
compared with the contracted, fibrotic organs encountered in 
many patients with postnecrotic cirrhosis. The recipient he-
patic artery is often friable in patients with PBC and is easily 
damaged during dissection. Construction of a new inflow 
vessel using a donor arterial homograft has proved to be a safe 
and durable method of arterial reconstruction in patients with 
an unsuitable native vessel. 
Several drugs, including colchicine, methotrexate, and 
cyclosporine. have been evaluated for their effects on the pro-
gression of bile duct damage and hepatic fibrosis in PBC. All 
have shown some efficacy, but their use has been limited bv 
toxicity. Most recently, ursodeoxycholic acid (ursodiol) ha's 
shown promise in a multicenter controlled trial. 120 Pro-
gression of disease is associated with jaundice, pruritus, 
fatigue, hepatic osteodystrophy, and, eventually, diminished 
hepatic synthetic function with hypoalbuminemia, periph-
eral edema, and prolonged prothrombin time. An increase in 
the progression of jaundice, total serum bilirubin level 
greater than 10 mg/dL, intractable pruritus, diminished he-
patic synthetic function, advancing bone disease, and vari-
ceal hemorrhage have been good indicators of the need for 
transplantation. Several statistical models have favorablv 
compared liver transplantation with other management strat-
egies, and such models may be useful in management plan-
ning.12.29.50.71.89 
Development of esophageal varices is common and often 
the major life-threatening complication ofPBC. In the Mayo 
Clinic experience, 31 % of patients who initially presented 
without esophageal varices subsequently developed them. Of 
these, 48 % had one or more episodes of hemorrhage. 49 Of 
those who bled, 33% did so within 1 year of diagnosis and 
41 %, within 3 years. We consider a history of variceal bleed-
ing to be a firm indication to evaluate the patient for liver 
transplantation. 
Rehabilitation after liver transplantation typically is good 
to excellent. 156 Encephalopathy, pruritus, and jaundice usu-
ally clear rapidly after successful liver transplantation. Skin 
xanthomas commonly regress within weeks. The deep skin 
pigmentation characteristic of patients with PBC may require 
several months to improve. Resolution of ascites depends on 
its severity before transplantation and on renal function. Var-
iceal bleeding is rare after successful liver transplantation, 
since the new liver provides the ideal relief of portal hyper-
tension. Particular attention must be paid to physical reha-
bilitation after liver transplantation to facilitate restoration of 
muscle mass and assist in recovery from bone disease. He-
patic osteodystrophy may be the most serious disabling com-
plication of PBC and can be slow to improve after transplan-
tation. Calcium and vitamin D supplements are routinely 
given, and braces to support patients with vertebral compres'-
sion fractures frequently are used. Despite these measures, 
some patients experience a long-term disability from severe 
osteodystrophy. Patients should be cautioned about the risk 
of fractures. 
Recurrence of PBC after liver transplantation was reported 
in three cases by the Cambridge groupl01 but has never been 
substantiated in our own experience. 156 Antimitochondrial 
antibodies usually remain positive after transplantation, even 
without evidence of disease in the graft. The Cambridge 
group subsequently reported finding pathology resembling 
that seen in PBC in liver grafts of recipients who did not have 
PBC as their original disease. 118 In a more recent study, the 
same group has reported liver biopsies taken beyond I year 
after transplantation for PBC showing features of the disease 
in 9 of 10 patients. 115 In 50 biopsy specimens from patients 
without PBC, 12 showed similar features of bile duct damage 
but with other distinguishing findings not suggestive of PBC. 
Further study is needed to resolve this question, since it may 
be difficult to discriminate between findings suggestive of re-
current disease, possibly altered by immunosuppression, and 
bile duct damage from chronic rejection. 
Biliary Atresia 
About 60% of liver transplantations performed in infants and 
children are for biliary atresia. Patient survival rates in the 
United States and Europe are 68% to 78% at 1 year and 68% 
to 75% at 5 years. Mortality is highest among small infants. 
Associated congenital anomalies are present in many of these 
children, including polysplenia, mid-gut mal rotations, pre-
duodenal portal vein, absent prerenal inferior vena cava with 
azygous continuation, situs inversus, symmetric liver, he-
patic arterial anomalies, and pulmonary anomalies. 62 These 
rarely preclude liver transplantation. 
The role of biliary drainage procedures for biliary atresia, 
especially the Kasai portoenterostomy, is being reassessed 
now that liver transplantation is a realistic alternative. Suc-
cess rates after hepaticoportoenterostomy vary from 30% to 
60%, depending on the authors' definition of success and the 
length of follow-up. In essence, less than one third of patients 
experience a long-term benefit of operation. After III suc-
cessful operations, Lilly and coworkers86 reported that 68 pa-
eventually died, including 55 from complications of 
Only 35 surviving patients had normal to near-
function. Grosfeld and colleagues51 reported 
results (clearing of jaundice) in 25% of patients. In 
recent report on patients surviving at least 10 years 
surgery for biliary atresia, it was stated that 80% of chil-
who underwent a Kasai procedure would eventually 
liver transplantation. 
. the limited prospects for avoiding liver transplan-
, in properly selected patients, the Kasai procedure still 
consideration. In patients in whom jaundice is 
normal growth and development can be expected. 75 
liver transplantation is eventually needed, valu~ble 
can be bought. Mortality after liver transplantation in 
infants has been higher than for older children, mostly 
of a higher incidence of technical complications, es-
hepatic arterial thrombosis. Improved methods of ar-
reconstruction and better preservation of the hepatic 
;"il'rnrlT' "f'1 . are reducing this risk. Donor organs are also 
difficult to find for young children. Piggyback place-
of donor organs on the recipient vena cava (see later 
w~I"u"K"I"r"! and reduced-size liver grafts are approaches to in-
the number of organs suitable for use in young chil-
1+.108.147 
The Kasai procedure is unlikely to succeed if performed 
120 days after birth, and the best chance of obtaining 
~prf[;Cepsnlj bile drainage is seen when operation is performed 
90 days of birth. Reoperation usually is fruitless if bile 
is not achieved at a first operation. Cholangitis is 
troublesome complication seen in patients with suc-
drainage and has a significant mortality.64 Surgical 
s: "'\JI\J" ' ... C1 ,,' 'u, used to control this include creation of stomal 
vents and conduit intussusception valves. 86 These procedures 
should be used with great discretion. A single Kasai proce-
does not add significantly to the technical difficulty of 
liver transplantation, but additional procedures often do. 
. Despite a technically successful operation, persistent jaun-
. dice, especially a serum bilirubin greater than 10 mg/dL, and 
. moderate jaundice with evidence of persistent portal hyper-
tension (esophageal varices) are indications for liver trans-
plantation.I.1i 
Infants and children with biliary atresia usually present 
.. , with severe nutritional deficiencies and growth retardation. 
. Fat-soluble vitamin and zinc deficiencies are common in pa-
tients with cholestasis. Attention to nutritional requirements 
in these patients is important. 24 
INBORN ERRORS OF METABOUSM 
After transplantation, a liver graft retains the synthetic func-
tions of the donor. In fact, a defect in donor hepatic synthesis 
of a coagulation factor has been incidentally conferred on a 
recipient. ll Liver transplantation has been performed in both 
adults and children for various diseases based on inborn er-
rors of hepatic metabolism. Jl5.136 About 7% of adults and 
30% of children have received transplants for these disorders, 
and patient survival has been high both in Europe and in the 
United States (see Table 43-1). In many of these conditions, 
such as Wilson's disease, ai-antitrypsin deficiency, tyrosin-
emia, and glycogen storage disease, the liver as well as other 
organs and tissues are affected by the disease. Correction of 
the metabolic defect is coincidental with treatment of the 
liver failure. 
In other conditions, such as oxalosis (type I hyperoxal-
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uria),94,163 familial hypercholesterolemia,8 and protein C de-
ficiency, 18 the liver itself is essentially normal but fails to pro-
duce a critical metabolite, resulting in severe systemic disease 
that affects other organs and tissues. Both type A and type B 
hemophilia have also been corrected by liver transplantation, 
although many of the liver replacements in such patients 
were required because of viral hepatitis ac~uired as a result of 
exposure to contaminated blood products. 7,43,84,96 
Experience with liver transplantation for inborn errors of 
metabolism has recently been reviewed by Starzl and co-
workers1l6 and is reproduced in Table 43-2, 
VASCULAR DISORDERS 
Acute Budd-Chiari syndrome with evidence of hepatocyte 
necrosis on liver biopsy may require portocaval or mesoatrial 
decompressive shunting. 57 Chronic Budd-Chiari syndrome 
with hepatic fibrosis is an indication for liver replacement. 
Excellent patient survival rates and a low incidence of recur-
rent disease can be obtained if patients are maintained on 
permanent anticoagulation therapy after transplantation. 17.14 
CANCER 
It was once hoped that liver transplantation would offer im-
proved prospects for cure of patients with malignant hepatic 
or biliary tract neoplasms that could not be satisfactorily 
managed by subtotal resection of the liver. Indeed, patient 
survival early after liver transplantation for cancer of the liver 
or biliary tree is high. Unfortunately, recurrent cancer within 
6 to 18 months of transplantation is common, even in pa-
tients in whom gross tumor appears to be confined to within 
the liver capsule and has not invaded the regional lymph 
nodes or the portal vein.68.76.105,11I Tumor histology, concur-
rent cirrhosis, lymph node involvement, and vascular inva-
sion influence the frequency and rapidity of recurrence. The 
liver graft frequently is an early site of recurrence, suggesting 
that microscopic nests of metastatic cells serve as a source of 
malignant cells able to home back to and thrive in the favor-
able environment of the new liver in an immunosuppressed 
host. 68 
Chronic viral hepatitis B, alcoholic cirrhosis, and hemo-
chromatosis are associated with an increased incidence of 
hepatoma. Slnall, incidental tumors (less than 2.5 cm in di-
ameter) may only be recognized at pathologic examination 
of the hepatectomy specimen, but such small lesions seldom 
are invasive and have a low incidence of recurrence. 
Fibrolamellar hepatoma is a better differentiated histologic 
variant of hepatocellular carcinoma that is not associated 
with cirrhosis, alcohol abuse, chronic B virus hepatitis, or 
use of oral contraceptives and tends to occur in younger pa-
tients. These tumors usually recur more slowly after liver 
transplantation than do conventional hepatomas, and the 
chance of cure may be somewhat higher. 97 Significant dis-
ease-free intervals have also been seen after liver transplan-
tation for epithelioid hemangioendothelioma, but results 
after liver transplantation for most other sarcomatous neo-
plasms have !reen poor. 
In children with tyrosinemia, progression to macronodu-
lar cirrhosis is associated with hepatoma formation. There-
fore, transplantation of children with tyrosinemia before age 
2 has been recommended. 26 
Results in children with liver transplantation for hepatob-
lastoma have been encouraging, with 50% survival reported 
, 
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TABLE 43.2 Inborn Errors of Metabowm 
Correction of A .. ociated Liver 
Duease CawelDescription MetaboUc Defect Longest Survival DuetUe 
Ill-Antitrypsin Structural abnonnality of protease Yes 13y Cirrhosis 
deficiency inhibitor synthesized in the 
liver 
Wilson's disease Abnonnal biliary copper Yes 16V2 y Cirrhosis 
excretions, decreased copper 
binding to ceruloplasm, copper 
accumulation in tissues, 
Autosomal recessive, gene 
mapped to chromosome 13 
Tyrosinemia Fumaroylacetoacetate hydrolase Nearly complete 7112 y Cirrhosis, 
deficiency hepatoma 
Type I glycogen storage Glucose-6-phosphatase deficiency Yes 7y Hepatomegaly, 
disease fibrosis, liver 
tumors 
Type IV glycogen Amylo-I,4-transglucosidase Incomplete 41/2 y Cirrhosis 
storage disease defect (branching enzyme) 
Cystic fibrosis Genetic defect recently identified. Not known 4V2 y Cirrhosis 
Pancellular disease often 
affecting the liver. 
Niemann-Pick disease Sphingomyelinase deficiency, Not known 2 y (died) None 
Sea-blue histiocyte 
sphingomyelin storage 
Unknown, neurovisceral No 7y Cirrhosis 
syndrome lipochrome storage 
Ery'thropoietic Hepatic ferrochelatase deficiency, Incomplete 1 V2 y Cirrhosis 
protoporphyria possible overproduction of 
protoporphyrin by 
erythropoietic tissues 
Crigler-Najjar Glucuronosyltransferase Yes 4y None 
syndrome deficiency 
Type I hyperoxaluria Peroxisomai alanine-glyoxalate Yes 8 mo None 
aminotransferase deficiency 
U rea cycle enzyme Ornithine carbamoyltransferase Yes 8mo None 
deficiency deficiency 
C protein d~ficiency Defective C protein synthesis Yes 2V4 y None 
Familial Low-density lipoprotein receptor Incomplete 6y None 
hypercholesterolemia deficiency, overproduction of 
low-density lipoprotein 
Hemophilia A Factor VIII deficiency Yes 4y Cirrhosis as a 
complication of 
blood 
component 
therapy 
Hemophilia B Factor IX deficiency Yes 6 rno Cirrhosis as a 
complication of 
blood 
component 
therapy 
(Adapted from Starzl TE, Oemtris AI. Van Thiel O. Medical progress: liver transplantation. N Engl J Med 321:1014, 1989) 
at 24 to 70 months of follow-up in the US experience. 77 Uni-
focal and intrahepatic tumors, tumors without microscopic 
vascular invasion, and tumors with predominantly fetal 
rather than embryonal or anaplastic epithelium have the best 
prognosis. The tumor may respond to chemotherapy, but a 
larger experience with combined chemotherapy and trans-
plantation is needed to determine efficacy. Resection of soli-
tary metastases may also be beneficial. One child with a sol-
itary pulmonary metastasis resected at 7 months after liver 
transplantation has remained tumor-free at 70 months of fol-
low-up. 
Dismal results have also been seen after liver transplanta-
tion for most lesions metastatic to the liver. Neuroendocrine 
tumors, however, may be more amenable to treatment, es-
pecially with techniques of extended total hepatectomy, 
which may also remove the insidious primary lesions. 139,158 
New approaches are needed to improve the prospects for 
treatment of liver and biliary tract cancers with transplanta-
tion. In carefully selected cases, liver transplantation com-
bined with aggressive application of chemotherapy or radio-
therapy may yet offer some hope to those affiicted with these 
formidable lesions. 
HEPATIC FAILURE 
management of fulminant hepatic failure WHF) r~­
a high level of expertise. Early transfer to a hver umt 
facilities for specialized monitoring, medical manage-
and transplantation services are available Kshoul~ be 
Special precautions are necessary during patient 
Patients with encephalopathy above stage II level 
be intubated to protect against aspiration. Survival de-
on cause, expert care, and, in cases compli~ated by 
'2d1(anCea stages of coma, cerebral edema, renal faIlure, or 
;Jl11;LCUJU1,'\.. acidosis, prompt replacement of the liver. 
The King's College Hospital Liver Unit found ,a strong 
correlation between survival (without transplantation) and 
'the cause of FHF. 104 Survival by etiologic group was fulmi-
hepatitis A, 66.7%; acetaminophen toxicity, 52.9%; ful-
minant hepatitis B, 38.9%; non-A, non-B hepatitis, 20.0%; 
and halothane or idiosyncratic hepatitis, 12.5%, Outcome 
was also correlated with complications, especially cerebral 
edema, oliguric renal failure, and uncompensated metabolic 
acidosis. Uncompensated metabolic acidosis was assOCiated 
with less than 10% survival. Only 37% of patients in stage 4 
~oma and 50% of patients in stage 3 coma survived. In s~b­
sequent studies, it has also been found that a contmued f~­
crease in prothrombin time on day 4 or a peak prothrombm 
time of 180 seconds or greater is associated with less than 8 % 
chance of survival in cases of acetaminophen overdose. 56 Ar-
, terial pH and serum creatinine levels also correlate with sur-
vival. In patients with viral hepatitis and drug reactions, age 
less than II years or more than 40 years, serum bilirubin 
,level greater than 300 ILmoi/L (17.5 mg/dL), and prothrom-
bin time greater than 50 seconds correlated with poor sur-
vival. 
. Of 42 patients who received liver transplants over a 7-year 
period for FHF in our Pittsburgh series, survival after trans-
plantation for HBV-related disease was 87,5%; for non-A, 
non-B hepatitis, 63%; and for toxic hepatitis, 33.3%. Only 5 
of 10 patients with stage IV encephalopathy who survived 
more than 1 week after transplantation had complete neuro-
logic recovery, 67 Vickers and colleagues161 also found a s~ong 
correlation between stage of encephalopathy and survival. 
Eighteen of 19 patients (95%) with stage I or II encephalop-
athy survived compared with only 13 of 38 patients (34%) 
with stage III or IV encephalopathy. 
With prompt recognition of poor prospects for medical re-
o covery and transfer to a liver transplant center, more than 
, 50% of patients with FHF can be saved. 33.67,161 Although this 
is not as good as can be achieved for patients with chronic 
liver failure, the results are a significant achievement, given 
the circumstances. 
PATIENT SELECTION AND 
PREOPERATIVE MANAGEMENT 
Evaluation of the candidate for liver transplantation includes 
establishment of the primary diagnosis, stage of disease, and 
prognosis; assessment of liver size and portal vein patency; 
and, in the case of patients with (or suspected of having) he-
'patic tumors, determination of the extent of disease. Most 
patients are referred to the transplant center with an estab-
, lished diagnosis and a poor prognosis without transplanta-
tion. A major gastrointestinal bleed, a history of repeated 
bouts of encephalopathy, progressive neuropathy, refractory 
ascites, a recent precipitous deterioration in liver function 
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(eg, a recent increase in the rate ~f rise of serum bilirubin 
level), rapid progression of, bone dls~aseI spontaneous ba7te-
rial peritonitis, poor hepatIc synthetic, funcho~I ~oss ,of liver 
volume, and progressive muscle wasting are mdlcations for 
early transplantation. , 
Portal vein patency usually can be determmed by ultra-
sonography or magnetic ~esonance imaging .(MRI), but oc-
casionally arteriography IS necessary. MRI IS probably the 
most reliable of the noninvasive screening studies for deter-
mining portal vein patency~ ~ut it is not always readil~ a~ail­
able. Portal vein thromboSIS IS not an absolute contraindica-
tion to liver transplantation, and venous phase arteriography 
may be necessary for adequate study of the mesenteric venous 
circulation. Computed tomography (CT) scans are useful to 
detect the presence of tumors, with ,or -w:ithout extrahepatic 
extension and can be used to determine lIver volume. Upper gastrointe~tinal endoscopy to check for var!ces .is ind~caIted in 
patients who have not had such an exammation Within the 
past 3 months. We do not recommend prophylacti~ sclero-
therapy if esophageal varices are present but the patient has 
no historv of bleeding. 
Patients with sclerosing cholangitis should have multiple 
endoscopic or percutaneous brushings of the biliary tree to 
evaluate for the presence of cholangiocarcinoma. Patients 
with liver masses detected by ultrasonography or cr scan 
should have an appropriate diagnostic evaluation for extra-
hepatic spread of disease. This includes CT examinations of 
the abdomen and chest and a bone scan. Blood tumor mark-
ers, including carcinoembryonic. antigen, vitamin BIZ bind-
ing protein, ferritin, a-fetoproteln, and PIKYA-2, are also 
screened in our protocols for the management of suspected 
tumor, If a neuroendocrine lesion is suspected, appropriate 
tests for these neoplasms should be performed. Baseline stud-
ies in preparation for chemotherapy include electrocardiog-
raphy, a multiple-gated acquisition heart scan, 24-hour cre-
atinine clearance, and biopsy proof of tumor. 
A complete serologic screen for, hepatitis A, B, an~ C 
should be performed. All patients Without demonstrable Im-
munity to hepatitis B should receive a complete ,course of 
recombinant vaccine for HBV, before transplantation If fea-
sible. As discussed previously, HBV carriers (HBsAg-positivel 
may benefit from administration of hIype~immu~e globulin 
beginning during surgery and con!lnumg mdefi~ltelyK 
Cytomegalovirus (CMV), vancella-zoster ViruS Es~sFI 
and Toxoplasma immunoglobulin tite~ should b~ ob~med 
as part of the pretransplantation evalu~tiM!lD C~s f~fectionsI 
both primary infections and reactivation mfections, are 
among the most common and most serious encountered after 
transplantation. Purified protein derivative (PPD) status must 
be known before transplantation. It is also important to know 
if the patient is anergic to other antigens, such as Trichophy-
ton, Candida, or mumps. Antiviral and antitubercular pro-
phylaxis are discussed in a later sec~onK " 
Attention to the nutritional reqUIrements of patients With 
liver failure is also important. Many such patients have severe 
deficiencies of fat-soluble vitamins and trace elements. 
MANAGEMENT OF PORTAL HYPERTENSION 
Ascites 
Refractory ascites can be a challe~gi~g ma~agem~nt problem 
and can lead to serious compiJcations, including sponta-
neous bacterial peritonitis and ulcerating umbilical hernia. 
Judicious use of diuretics and colloid is required, and large-
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volume paracentesis is recommended for severe cases. Peri-
toneal-venous shunts (LeVeen shunt, Denver shunt) can be 
useful and can easily be removed at the time of transplanta-
tion. In our experience, the use of these shunts is associated 
with the formation of inflammatory intraabdominal adhe-
sions, possibly from recurrent episodes of spontaneous bac-
terial peritonitis, which can make the transplantation proce-
dure more difficult. Patients with previous failed shunts 
should have a Doppler ultrasound examination before trans-
plantation to evaluate the patency of the jugular and subcla-
vian veins. Thrombosis of these vessels is a complication of 
failed shunts and can make venous bypass access difficult or 
impossible during transplantation. 
Variceal Hemorrhage 
Before the availability of liver transplantation, the role of the 
surgeon in the management of variceal bleeding from portal 
hypertension was directed at prevention of rebleeding. Bal-
loon tamponade, selective or peripheral infusion of vasopres-
sin, transthoracic variceal ligation, and nonselective porto-
systemic shunts were the classic approaches taken. In the 
elective setting, the selective distal splenorenal shunt has be-
come the operation of choice, and it may still be the preferred 
procedure in patients with good hepatic reserve (Child's class 
A patients). For most patients with significant underlying 
liver disease, transplantation is required, and shunt proce-
dures should be reserved only for such patients whose hem-
orrhage cannot be controlled by conservative measures, such 
as balloon intubation or sclerotherapy, and for whom a liver 
cannot be found or for whom transplantation is contraindi-
cated for other reasons. 
Sclerotherapy is a preferred method for controlling acute 
variceal hemorrhage in patients with portal hypertension. 
Acute bleeding is reported to be controlled in 80% to 95% of 
patients by sclerotherapy performed by a skilled endoscopist. 
although eventual rebleeding can be expected in 38% to 60% 
of patients. 12 
In our experience, emergency sclerotherapy for acute 
bleeding in liver transplantation candidates has a high rate 
of complications (69.4%), including esophageal stricture 
(56.0%), bleeding esophageal ulcers (10.5 %), and esophageal 
perforation (2.9%).112 For this reason, in the acute setting, 
we prefer to first use balloon tamponade and peripheral va-
sopressin to stabilize the patient with massive hemorrhage. In 
the elective setting, the rate of complications is much lower 
(12.6%), including esophageal stricture (9.0%), bleeding 
esophageal ulcers (3.1 %), and esophageal perforation (0.5%). 
Esophageal transection and devascularization procedures 
should be avoided because severe scarring may result that can 
make liver transplantation extremely difficult. Some recent 
reports suggest that percutaneous transjugular placement of 
an intrahepatic stent-shunt may be a valuable technique in 
patients waiting for a liver transplant to control portal hyper-
tension without invasive surgery.1H.1Z5 If an emergency sur-
gical shunt is needed to control persistent or recurrent hem-
orrhage, a mesocaval shunt is preferred, since this avoids 
dissection in the hepatic hilum, but even a portocaval shunt 
does not make liver transplantation prohibitive. Survival rates 
after liver transplantation in patients with or without a history 
of variceal hemorrhage and in those with or without a history 
of a shunt procedure are not significantly different. 1.66 
Finally, acutely bleeding patients can be managed by im-
mediate liver transplantation. The transplant corrects the un-
derlying liver disease and provides immediate portal de-
compression. Most patients stop bleeding once the graft is in 
place. Unfortunately, a suitable liver graft seldom is available 
on such an urgent basis. 
CONTRAINDICATIONS TO 
UVER TRANSPLANTATION 
There are few absolute contraindications to liver transplan-
tation. Severe systemic conditions, not also amenable to 
medical or surgical correction, may contraindicate liver 
transplantation if the ability of the patient to withstand the 
stress of operation is in serious doubt, the life expectancy of 
the patient would not be significantly prolonged, or a poor 
quality of life would not be improved. Uncontrolled sepsis 
outside the liver or biliary tree, acute hemodynamic instabil-
ity with compromise of other vital organs, active substance 
abuse, extrahepatic or metastatic cancer (with some excep-
tions as noted previously), irreversible brain damage or neu-
rologic dysfunction, and a history of behavioral or psychiatric 
disorders that would interfere with the patient's ability to 
comply with the necessary medical regimen are contraindi-
cations to liver transplantation. Spontaneous bacterial peri-
tonitis should be treated for at least 48 hours and preferably 
for 7 days before liver transplantation is attempted. 
Advanced age was once considered to be a contraindica-
tion, but excellent results have recently been reported for pa-
tients over age 60. 141 The oldest patient to receive a liver graft 
in Pittsburgh was 76 years old at the time of operation, and 
as of this writing, she is alive and well at age 81. 
Most problematic is whether or not patients with posi-
tive serology for the human immunodeficiency virus (HIV) 
should be candidates for liver transplantation. 136 A retrospec-
tive survey of stored sera from patients given liver transplants 
between 1981 and 1986 revealed a 2.6% incidence of HIV 30 
HIV antibodies predated the transplantation in one third of 
these recipients, and the rest seroconverted afterward. Among 
the 10 children in the HIV-positive group, only I died of a 
complication related to HIY. Among the 16 'adults in this 
series. the acquired immunodeficiency syndrome (AIDS)-
related mortality was 37%. 
It is clear that HIV positivity carries an increased risk of 
AIDS-related morbidity and mortality in the transplant pop-
ulation. Many patients who, despite evidence of past expo-
sure to HIV, are still free of clinical manifestations of AIDS 
can receive substantial, prolonged benefit from liver trans-
plantation. For these patients, the immediate threat is end-
stage liver disease, not AIDS, and these patients can do well 
despite the risks of immunosuppression required for trans-
plantation. 
Intrapulmonary shunting with hypoxemia is a complica-
tion of advanced liver disease and sometimes has been con-
sidered a contraindication to liver transplantation. After 
transplantation, the shunts eventually close and the extra-
pulmonic manifestations reverse. 1+4 In severe cases, this can 
take several months, and an extended period of ventilatory 
support may be required. Patients with significant pulmonary 
artery hypertension, however, usually cannot tolerate opera-
tion. Therefore right-sided heart catheterization should be 
performed before surgery to measure pulmonary artery pres-
sure. 
Patients with the most advanced degrees of muscle wasting 
and nutritional deprivation may be unable to survive liver 
transplantation. If operation is attempted in severely debili-
tated patients, tracheostomy should be considered at the same 
. time as transplantation, since these patients inevitably also 
require prolonged ventilatory as well as intensive nutritional I support after surgery. 
.>< 
i+: Organ Preservation 
The University of Wisconsin (UW) preservation solution in-
c; traduced in 1987 by Belzer and Southard7•70.71 represents the 
first major advance in liver preservation since the original 
descriptions of slush preservation more than a decade earlier. 
Using this solution, it has been possible to extend liver pres-
ervation from a mean preservation time of about 5 hours to 
12 hours and to extend the limits of preservation out to at 
least 18 hours with comparable quality of graft function and 
a low incidence of primary graft failure. 20.106.114.152 Although 
we have seen perfect liver function even with organs kept in 
cold storage in UW solution for 20 to 34 hours, the rate of 
retransplantation and the incidence of primary graft failure 
increase significantly with longer preservation times-l2 (Fig. 
43-6). It is, therefore, recommended that organs be used 
within 20 hours of storage. 
The practical benefits of longer preservation time are sig-
nificant, and this has changed liver transplantation from an 
. urgent operation to a semielective procedure in many cases. 
Patients have more time to be called in to the transplant cen-
ter for surgery, and thus, more patients can wait at home. 
Grafts can be sent to transplant centers from distant sources. 
Surgeons can explore patients and have time to arrange for a 
backup patient if the intended recipient proves to be inoper-
able. 
The incidence of primary graft failure after liver transplan-
tation is 5% to 10% in most reported series. There is no ac-
cepted and reliable test to predict which grafts will function 
and which will fail before implantation. Pretransplantation 
biopsies can be useful if certain findings are present. Signif-
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icant fatty infiltration (macrovesicular steatosis),25.148 exten-
sive ballooning of hepatocytes (hydropic degeneration), 25 and 
pericentral and pan lobular individual hepatocyte necrosis88 
are associated with a higher risk of primary graft failure. In 
postperfusion biopsies, the presence of zonal or severe focal 
necrosis and a severe neutrophilic exudate (findings that may 
suggest hyperacute rejection) have been associated with a dif-
ficult postoperative course but not with inevitable graft fail-
ure.72 A normal pretransplantation biopsy is not a guarantee 
of graft viability, since irreversible subcellular ischemic dam-
age may not be detectable with conventional histology. 
Availability of a simple, rapid test for graft viability would 
significantly reduce the incidence of primary graft function. 
MEGX, a metabolite of lidocaine, has been compared favor-
ably with other methods of assessment, such as indocvanine 
green clearance, and is easily and rapidly measured. 102 It has 
shown some promise as a test of pretransplantation graft via-
bility, but prognostic sensitivity and specificity are only about 
75%.101 It may prove useful when used in combination with 
other parameters of graft quality. 
p~crumrocedure 
Details of the operative techniques of liver transplantation are 
beyond the intended scope of this chapter and have been ad-
dressed elsewhere. -I6.1l7 In brief, the operation is performed 
in four stages. The first stage, recipient hepatectomy, can be 
formidable if the patient has had extensive previous surgery 
in the upper abdomen, has a severe, uncorrectable coagulop-
athy, or has a small contracted liver. The second, an hepatic 
phase, during which the recipient vessels are anastomosed to 
the vessels of the graft, has been greatly facilitated in larger 
children and adults by routine use of a partial veno-venous 
bypass. The bypass effectively decompresses the systemic and 
mesenteric venous drainage and maintains delivery of an ad-
equate blood volume to the right side of the heart during the 
period of interruption of the suprarenal inferior vena cava 
and portal vein. This reduces mesenteric venous congestion, 
renal vein hypertension, and bleeding from the usually rich 
and fragile venous collateral bed in patients with long-stand-
ing portal hypertension. The third phase begins on revascu-
larization of the new liver, when both surgical and medical 
bleeding commonly is encountered, and requires consider-
able skill on the part of both the surgical and the anesthesia 
teams to control. Once hemostasis has been achieved, the 
final stage of the procedure, a biliary reconstruction, is per-
formed. 
INFERIOR VENA CAVA 
In the conventional reconstruction, the suprahepatic vena 
cava of the graft is anastomosed end to end to a cuff of infra-
diaphragmatic recipient inferior vena cava followed by anas-
tomosis of the infrahepatic graft vena cava end to end to a 
cuff of suprarenal recipient inferior vena cava. The intrahe-
patic portion of the recipient vena cava is removed with the 
native liver. The right adrenal vein must be ligated, and this 
can lead to venous infarction of the gland with hemorrhage. 
An alternative to the standard technique is to piggyback 
the suprahepatic portion of the graft vena cava to the conflu-
ence of the recipient hepatic veins and oversew the infrahe-
patic end of the graft vena cava. 151 The native liver is first 
l' 
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carefully dissected off the recipient vena cava, which is left 
in place (Fig. 43-7). The right adrenal vein is, therefore, left 
intact. The end of the infrahepatic graft vena cava is simply 
oversewn. 
The piggyback approach can be. advantageous in selected 
cases in which the graft size is mismatched with the recipient 
or there is a large discrepancy in the diameter of the recipient 
and graft venae cavae. It provides an alternative to the use of 
the veno-venous bypass, since the recipient vena cava is left 
in continuity, and is, therefore, a method of choice in pa-
tients in whom venous bypass cannot be used, such as pa-
tients with thrombosis of the subclavian veins after failed 
peritoneal-venous shunts. Care must be taken to avoid ex-
cessive traction on the vena cava during dissection, which 
might obstruct blood flow. The longer period of portal vein 
obstruction endured with this approach may predispose to 
translocation of infectious organisms from the gut during a 
FIGURE 43·7 The piggyback technique for implan-
tation of a liver allograft with preservation of the recipient 
inferior vena cava. (A) After completion of the hilar dis-
section, the left lobe is rotated, individual hepatic veins 
are ligated, and the main hepatic veins are exposed. (B) 
If difficulty is encountered in exposing the hepatic veins. 
the parenchyma can be split and the veins controlled 
from inside the liver. (C) The hepatic vein cuffs are pre-
pared for anastomosis. The middle and left hepatic veins 
usually are used for anastomosis and the right hepatic 
vein is oversewn, as shown here. (0) The completed im-
plant lying on the intact recipient vena cava. The infra-
hepatic portion of the graft vena cava has been oversewn. 
(Tzakis A, et al. Orthotopic liver transplantation with 
preservation of the inferior vena cava. Ann Surg 210:649, 
1989) 
period of splanchnic congestion and increase the risk of post-
operative sepsis. The cuff of vena cava constructed from the 
recipient hepatic veins must be generous enough to provide 
for unobstructed outflow, and the liver must not be free to 
twist in the abdomen on the axis of the vena cava anasto-
mosis. 
Advanced cirrhosis may result in retrograde portal vein 
flow, which may progress to portal vein thrombosis. Throm-
bosis may involve only the main portal vein or may also in-
volve the mesenteric or splenic veins (Fig. 43-8). This is also 
a potential complication of central or selective portosystemic 
shunting procedures. Cavernous transformation of the portal 
vein with generous venous collaterals in the hilum may de-
velop, and ultrasonographers may mistake this high venouS 
flow for a patent portal vein. Even if thrombosis of the portal 
vein does not occur, the vein wall may become diseased, ren-
dering the vessel unsuitable for anastomosis. 
Q 
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If the confluence of the mesenteric and splenic veins is 
suitable, a graft of iliac vein from the liver donor can be used 
to extend the recipient portal vein (Fig. 43-9). In rare cases, 
a large collateral vein, such as a coronary vein or a chole-
dochal vein, has been used for anastomosis to the portal vein. 
In most patients, however, it is possible and preferable to con-
struct a venous jump graft of donor iliac vein from either the 
superior mesenteric vein or one of its large branches. such as 
the right colic vein, to the graft portal vein B I.lH.I54 (Fig. 43-
10). This graft can be tunneled through the transverse me-
socolon. over the pancreas, and beneath the pylorus to 
emerge in an ideal location for anastomosis, a route also used 
for arterial grafts. If venous phase arteriography fails to visu-
alize a suitable mesenteric vein in a patient with portal vein 
thrombosis, it may be necessary to explore the patient to de-
termine if such revascularization is feasible and to have a 
backup patient available if it is not. 
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HEPATIC ARTERY 
Hepatic artery thrombosis is one of the most common and 
dreaded technical complications after liver transplantation. It 
is best prevented by meticulous surgical technique and liberal 
use of alternative reconstruction techniques if there is any 
doubt about the integrity of a conventional anastomosis. In 
most adult patients, the celiac artery of the graft is sewn end 
~o end to the common hepatic artery of the recipient. In 
young children, the anastomosis may be placed closer to the 
recipient aorta at the level of the celiac axis. In about 12% of 
adults and 50% of children, the native recipient artery is un-
suitable for anastomosis and a new hepatic artery must be 
reconstructed. 151 This usually is performed by anastomosis of 
the donor hepatic or celiac artery to an iliac artery graft taken 
from the liver donor and placed on the anterior surface of the 
proximal infrarenal recipient aorta. The graft is tunneled 
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through the transverse mesocolon, over the pancreas, and be-
hind the pylorus1s7 (Fig. 43-11) or posterior to the superior 
mesenteric artery, duodenum, and pancreas to emerge be-
tween the inferior vena cava posteriorly and the portal vein 
anteriorly. 
BILIARY RECONSTRUCTION 
When possible, direct end-to-end anastomosis of the recipi-
ent bile duct to the donor bile duct over aT-tube stent exter-
nalized through a stab wound in the distal recipient duct is 
the preferred method of biliary tract reconstruction (Fig. 43-
12, inset). The ampulla of Vater is preserved and the T-tube 
permits monitoring of the quantity and quality of bile output 
and radiographic examination of the biliary tract. Progressive 
dilatation of the bile duct, presumably from spastic dysfunc-
FIGURE 43·9 (A) Portal vein reconstruction using a long donor 
portal vein anastomosed to the splenic vein-superior mesenteric 
vein confluence. (B) Reconstruction of the portal vein using an in-
terposition graft of donor iliac vein. (Stieber AC, et al. The spec-
trum of portal vein thrombosis in liver transplantation. Ann Surg 
213:199, 1991) 
FIGURE 43.8 Patterns of thrombosis of the portal 
vein in advanced cirrhosis. (Stieber AC, et al. The 
spectrum of portal vein thrombosis in liver transplan. 
tation. Ann Surg 213:199, 1991) 
han of a denervated ampulla of Vater, is a common compli-
cation that can necessitate conversion to a Roux-en-Y cho-
ledochojejunostomy. Leaks and strictures are also important 
complications (discussed further under technical complica-
tions). 
End-to-side anastomosis of the donor bile duct to a Roux-
en-Y limb of proximal jejunum is the preferred alternative to 
duct-to-duct reconstruction and is the method of choice in 
patients with disease of the extrahepatic bile ducts (see Fig. 
43-12). Although more complex, it has proved to be a dura-
ble and reliable method of reconstruction. Ascending chol-
angitis is uncommon after this reconstruction when properly 
performed. Bile leak after this reconstruction can be more 
serious than after duct-to-duct reconstruction because of 
open bowel contamination of the abdominal cavity. Contrast 
examination of the biliary tree requires percutaneous chol-
angiography. 
Another technique of biliary reconstruction that uses the 
donor gallbladder as a conduit between the donor and the 
recipient bile ducts has a few advocates (Fig. 43-13). We have 
limited use of this reconstruction to highly selected cases 
when previous surgery has caused extensive scarring or pre-
vious extensive intestinal resection prohibits reconstruction of 
an appropriate Roux limb for choledochojejunostomy. In our 
experience, half of these reconstructions were complicated by 
biliary stones or sludge formation. 53 The King's College Hos-
pital group reported abnormal cholangiograms in 80% of pa-
tients with this type of reconstruction who were observed for 
3 years. Findings included biliary strictures, inspissated bile, 
bile leak, and malpositioned T-tubes. l6 This method has 
been used by Wall and associates l62 in London, Ontario, 
without a T-tube or internal stent with a reported complica-
tion rate of 13.6%. 
Postoperative Care 
Postoperative care of the liver transplant recipient is demand-
ing and requires a lifelong commitment to the patient. Mis-
takes in management after surgery are just as dangerous as 
I 
FIGURE 43·10 Portal vein reconstruc· 
tion using a jump graft of donor iliac vein 
from the superior mesenteric vein to the 
. donor portal vein. The graft is passed 
through a tunnel in the base of the trans· 
verse mesocolon, superior to the pancreas 
and inferior to the distal stomach, to 
reach the hepatic hilum. This is the pre-
ferred method of reconstruction when the 
recipient portal vein and the confluence 
; of the mesenteric and splenic veins are 
thrombosed but the main superior mes-
enteric vein is patent. (Tzakis AG, et al. 
Venous jump grafts for liver transplanta-
tion in patients with portal vein throm-
bosis. Transplantation 48:530, 1989) 
technical misadventures in the operating room. Coordina-
tion of effort and continuous liaison between the transplant 
center staff and primary care providers are essential to the 
patient's welfare. 
EARLY POSTOPERATIVE RECOVERY 
In typical cases, if the graft functions well immediately after 
implantation and the recipient has no extraordinary risk fac-
tors, a prompt recovery with a 24- to 48-hour stay in the 
intensive care unit and a 14- to 21-day stay on the regular 
hospital floor can be anticipated. In many respects, the care 
of the postoperative liver transplant recipient resembles the 
care of other general surgical patients, but there are some 
important differences. 
On leaving the operating room, the patients are always in 
a state of volume excess with considerable third spacing of 
fluid, but many patients are oliguric for 24 to 48 hours. Di-
uretics and colloid often are required, but crystalloid should 
be limited to modest maintenance requirements to avoid pul-
monary edema. Potassium should be given as an intermittent 
infusion when needed rather than added to maintenance 
fluids. Graft necrosis (primary nonfunction, hepatic artery 
thrombosis, hyperacute rejection) can result in sudden in-
creases in serum potassium levels. Hypertension is common 
and must be treated aggressively. The moderate prolongation 
of prothrombin time and the thrombocytopenia commonly 
seen early after liver transplantation when combined with hy-
pertension leave the patient at significant risk of intracerebral 
bleeding. 
Except in patients with active bleeding, a prothrombin 
time elevated within 15 to 20 seconds of control and platelet 
counts as low as 30,OOO/ILL are not corrected. Inappropriate 
correction of moderate coagulation abnormalities may con-
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mesenteric vein 
tribute to hepatic artery thrombosis, especially in children. 
Patients at high risk of vascular thrombosis, such as young 
children, are anticoagulated with low-molecular-weight dex-
tran (Dextran 40), 5 mUh intravenously for 5 days, and given 
aspirin and dipyridamole (.Persantine). Once the prothrom-
bin time is less than 18 seconds, heparin, 50 IUIkg subcuta-
neously, is given every 12 hours. This regimen seldom is 
needed in adult patients. 
Intraabdominal bleeding and primary graft failure are the 
two most common major problems seen in the immediate 
postoperative period. Reexploration is advised for the patient 
who bleeds significantly after surgery, even if the patient sta-
bilizes. If the abdomen is distended with blood or noninva-
sive imaging studies show a significant volume of clot in the 
abdomen, it is best to evacuate the abdomen and check the 
integrity of all vascular anastomoses, lest one be faced with 
an infected hematoma or a false or mycotic aneurysm later. 
Patients who require blood should not be permitted to be-
come hypotensive or anuric before reexploration is consid-
ered. 
Primary graft failure may not be evident immediately be-
cause some grafts have partial function for a few days before 
it becomes evident that the liver cannot sustain the patient. 
Causes of immediate graft failure include ischemic preser-
vation injury, vascular thrombosis, and hyperacute rejection. 
Persistent abnormal liver function tests, uncorrectable pro-
longation of the prothrombin time, elevated lactate levels, 
oliguria, and central nervous system (CNS) changes (leth-
argy, seizures) are the common early findings. Narcotics and 
sleep medications should be avoided early after liver trans-
plantation, since they impair assessment of CNS status. Bed-
side Doppler ultrasound studies are useful in assessing the 
patency of the portal vein and hepatic artery. Coma, alka-
losis, hyperkalemia, and hypoglycemia characterize the ad-
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FIGURE 43-11 Route of a freestanding donor iliac arterial graft 
from the infra renal abdominal aorta to the hepatic hilum. The graft 
passes through a rent in the transverse mesocolon (not shown) to 
pass anterior to the pancreas and behind the pylorus. Note the 
anomalous donor arterial supply to the liver graft with separate 
origins of hepatic arterial branches. Complex donor arterial anom-
alies are best handled by this method of reconstruction. (Tzakis AG, 
et al. The anterior route for arterial graft conduits in liver transplan-
tation. Transplant lnt 2: 12 I, 1989) 
vanced stage of primary graft failure. Potassium infusions 
must be avoided, and dextrose 10% in water may need to be 
given to support blood glucose levels. Ultimately, only urgent 
retransplantation before pneumonia or irreversible coma sets 
in can save the patient with primary graft failure. 
COMPLICATIONS 
Technical complications are common after liver transplan-
tation and associated with an increase in postoperative mor-
tality. Postoperative bleeding and biliary leak or obstruction 
are the most common complications that require reopera-
tion. 83 
Intraabdominal bleeding early after surgery has already 
been discussed and usually is the result of technical prob-
lems. Another rare but important cause of hemorrhage is 
rupture of a preexisting splenic artery aneurysm.l,ll These 
lesions may be identified on preoperative studies such as CT . 
scans and ultrasonography. At the time of transplantation, 
the course of the splenic artery along the upper margin of the 
pancreas should be palpated. If a splenic artery aneurysm is 
present, the artery should be ligated. 
Biliary Complications 
Biliary leak or obstruction are amon~ the most frequent com-
plications after liver transplantation. 26.146 The most common 
site of biliary leakage after liver transplantation is from the 
exit site of the T-tube from the common bile duct in patients 
with a duct-to-duct reconstruction, The diagnosis is con-
firmed by cholangiography. If the leak is discovered in-
cidentally on a routine cholangiogram and the patient is 
asymptomatic, no treatment may be necessary. Even most 
symptomatic leaks are minor and can be managed by retro-
grade endosco~ic placement of a nasobiliary stent or simple 
suture repair. 1 7 Leaks from the duct-to-duct anastomosis are 
more serious, and most require reconstruction by conversion 
to a Roux-en-Y choledochojejunostomy. Simple suture re-
pair usually fails. If the leak is the result of necrosis of the 
duct from hepatic artery thrombosis, external drainage of the 
biliary tree may be required until retransplantation can be 
performed. 
Most T-tube stents are removed about 3 months after 
transplantation. This may be accompanied by bile leakage. 
FIGURE 43.12 Methods of biliary re-
construction. Roux-en-Y choledochoje-
junostomy over an internal stent and 
choledochocholedochostomy over a T-
tube stent (iruet). 
FIGURE 43.13 Waddell-Caine biliary conduit. 
(Adapted from Halff G, et al. Late complications with 
gallbladder conduit biliary reconstruction after liver 
transplantation. Transplantation 48:537, 1989) 
Patients complain of abdominal .or shoulder pain, usually 
within I hour of T-tube removal. Symptomatic patients 
should be observed in the hospital and kept lying on the right 
side. If symptoms persist and signs of peritonitis progress, the 
patient should be explored and the T-tube exit site sutured to 
stop the leak. 
Leaks from the choledochojejunostomy after a Roux-en-
, Y limb reconstruction are less common but more serious be-
cause of the violation of the intestinal tract. A fresh anasto-
mosis to a less inflamed site on the Roux-en-Y limb should 
be performed when feasible. If severe infection is present, 
'external drainage and deferred reconstruction may be re-
" quired. Necrosis of the bile duct from hepatic artery throm-
, basis should be suspected. 
Biliary strictures typically occur later in the postoperative 
course and may present insidiously with alterations in liver 
function similar to those seen with rejection, hepatitis, or 
drug toxicity. Liver biopsy, hepatitis serology, ultrasonogra-
phy, and cholangiography are used to make the differential 
diagnosis. Patterns of biliary obstruction include anastomotic 
stricture, donor distal duct narrowing, multiple intrahepatic 
, strictures, dilatation of the donor and recipient ducts without 
a demonstrable point of obstruction, iatrogenic obstruction 
by T-tubes or internal stents, and unusual causes, such as a 
mucocele of the cystic duct stump,170 or recurrent biliary 
, tract disease, such as sclerosing cholangitis or cancer. 58 
! An indwelling catheter, which usually can be placed per-
, cutaneously by the interventional radiologist, should be left 
in patients with a demonstrable obstruction at cholangiogra-
phy. If the obstruction is localized, balloon cholangioplasty 
may be tried. Obstructions with biliary stones or biliary di-
'latation without an obvious site of obstruction (as commonly 
is seen in patients with ampullary dysfunction after a duct-
, to-duct reconstruction) require surgical correction (usually 
conversion to a Roux-en-Y choledochojejunostomy) or en-
sphincterotomy. An obstructing mucocele is re-
intrahepatic strictures present a more difficult 
. Hepatic artery thrombosis or stricture may be the 
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cause. Biliary stenting and, occasionally, balloon dilation 
may be useful in achieving some decompression of the biliary 
tree, but surgical correction by retransplantation usually is 
necessary. In those cases in which the strictures are confined 
to an appropriate anatomic distribution in the liver, subtotal 
hepatic resection can be done. 
Vascular Complications 
Hepatic artery thrombosis is one of the most serious compli-
cations after liver transplantation. It usually is the result of a 
technical error, but it can also result from preservation injury 
of the graft with ischemic injury to the hepatic microcircu-
lation, inappropriate correction of coagulation parameters af-
ter operation, high hematocrit, a posttransplantation hyper-
coagulable state, and uncontrolled allograft rejection with 
increased intrahepatic vascular resistance and in association 
with pancreatitis. 4,92. 134.169 
Arterial thrombosis should be suspected in any liver trans-
plant recipient with a sudden high temperature and an ele-
vation in liver function studies. Blood cultures that grow en-
teric organisms (Klebsiella sp, Escherichia coli, enterococci) 
are almost pathognomonic. Doppler ultrasonography is an 
effective noninvasive screening device,.o but arteriography is 
necessary even if ultrasonography is negative when there is a 
high index of clinical suspicion. 
Hepatic arterial thrombosis has three general presenta-
tions: (1) acute hepatic gangrene with fulminant liver failure, 
(2) delayed biliary leak with or without bile abscess, and (3) 
relapsing bacteremia with minimal, if any, liver dysfunction. 
Treatment depends on cause and presentation. If a technical 
flaw is quickly identified, immediate sur~ical correction 
sometimes is possible and can save the graft. 1 8 In a few cases, 
hepatic arterial thrombosis has been successfully treated with 
intravascular fibrinolytic therapy. 59 Acute hepatic gangrene 
requires urgent retransplantation. Bile duct necrosis also re-
quires retransplantation but can be controlled with antibiotics 
and appropriate surgical drainage until a new graft can be 
found. Relapsing bacteremia is treated with intravenous an-
tibiotics followed by a course of oral suppressive therapy. If 
j 
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the patient remains afebrile with satisfactory liver function, 
retransplantation may be avoided or only become necessary 
when chronic ischemic biliary strictures develop. Most pa-
tients with persistent bacteremia and most of those who de-
velop intrahepatic abscesses require retransplantation. Per-
cutaneous drainage of an intrahepatic biloma or abscess 
usually is only a temporizing maneuver. ;.j 
Portal vein thrombosis is much less common than hepatic 
artery thrombosis. It may result in fulminant graft failure, 
especially when it occurs soon after transplantation, but it 
should also be suspected in patients with severe ascites or a 
variceal hemorrhage after transplantation. In patients with a 
viable graft but complications of portal hypertension, a distal 
splenorenal shunt has been used successfully. 87.128 
Complications of the vena cava anastomoses are rare. Ste-
nosis of the suprahepatic inferior vena cava anastomosis may 
impair venous drainage enough to cause a Budd-Chiari syn-
drome and should be considered in any patient with persist-
ent, massive ascites after an otherwise successful liver trans-
plantation. Percutaneous transluminaI balloon dilatation has 
been successfully used in some cases as an alternative to sur-
gical repair or retransplantation. 171 
Intestinal Complications 
Bowel obstruction is uncommon after liver transplantation. 
Most adhesions are confined to the supracolic portion of the 
abdomen. If the base of the mesenterY of a Roux-en-Y limb 
is not tacked down, the small bowel'may herniate through 
and obstruct. Overuse of aluminum-containing antacids may 
result in inspissation and obstruction of the intestine. Pseudo-
obstruction of the colon is much less common than after re-
nal transplantation but must be treated aggressively to avoid 
disastrous colon perforation, 
The gastrointestinal tract is one of the common sites for 
Iymphoproliferative lesions in immunosuppressed patients, 
and these may obstruct or perforate the bowel. Segmental 
resection of involved bowel is recommended for localized le-
sIOns. 
Most intestinal perforations that occur early after trans-
plantation are anastomotic leaks, perforation in an area of 
denuded serosa, or perforation of bowel injured by electro-
cauterY. Anastomotic leaks are more common in children 
and should be suspected whenever there is evidence of in-
traabdominal polymicrobial or candidal infection. Hematog-
enous or abdominal wound candidiasis is also suggestive of a 
violation of the gut. Prompt surgical exploration is indicated. 
Most late perforations are caused by diverticulitis, appendi-
citis, CMV enteritis, or lymphoproliferative lesions. 
Gastrointestinal Bleeding 
Bleeding may occur anywhere in the gastrointestinal tract af-
ter liver transplantation. Endoscopy, radionuclide scanning, 
and angiography are indicated to localize the bleeding site. 
A common site of bleeding after liver transplantation in pa-
tients with a Roux-en-Y biliary reconstruction is from the 
suture line of the jejunojejunostomy. The bleed typically is 
from a single arteriole and usually can be managed by open-
ing the anterior portion of the anastomosis to find and repair 
the site. Less commonly, the bleeding is from the closed end 
of the Roux loop. Variceal hemorrhage after liver transplan-
tation suggests either portal vein thrombosis or esophageal 
stricture. 
Mucous ulceration of the esophagus, stomach, small 
bowel, or colon may result from opportunistic infection 
such as in CMV gastroenteritis or colitis and Clostridium dif. 
ficiIe pseudo~embranous colitis, and present with bleeding. 
Management IS red blood cell replacement, reduction of im. 
munosuppression, and appropriate antibiotic therapy (eg 
ganciclovir, metronidazole [Flagyl]). Total colectomy or su~ 
total gastrectomy is only necessary in unusually severe or per. 
sistent cases. 
A rare but particularly dangerous cause of gastrointestinal 
bleeding after liver transplantation is a fistula between the 
gastrointestinal tract and a vascular anastomosis, either the 
hepatic arterial anastomosis or anastomosis of an iliac artery 
conduit to the aorta. Ligation of the involved vessel usually 
is required, since most of these fistulas are the result of an 
infected false aneurysm, often with Candida, and cannot be 
repaired primarily without a high risk of breakdown and hem. 
orrhage. In some cases, the liver has tolerated arterial ligation 
and retransplantation has not been necessary. 
Ascites 
Ascites may persist for several weeks or months after liver 
transplantation. Technical faults, such as portal vein or suo 
prahepatic inferior vena cava obstruction or thrombosis, 
should be ruled out. Ascites usually can be managed with 
salt restriction and diuretics and gradually diminishes with 
time. In some cases, placement of a peritoneal-venous shunt 
may be required. Late recurrence of ascites suggests cirrhosis 
and should be investigated to determine its cause (rejection, 
hepatitis, recurrence of original disease), 
Pancreatitis 
Many patients have a mild, asymptomatic pancreatitis with a 
mild ileus and modest hyperamylasemia (500 IU/dL) early 
after liver transplantation. This usually resolves without se-
quelae. Edema and enlargement of the pancreas on a CT 
scan or ultrasound are more ominous and may lead to ab-
scess, pseudocyst, and, occasionally, frank hemorrhagic pan-
creatitis. 
The cause of pancreatitis after liver transplantation is un-
certain but may be multifactorial. Manipulation of the pan· 
creas during dissection of the hepatic artery or creation of 
tunnels for vascular grafts, ischemic insult from ligation of 
the gastroduodenal artery, venous congestion of the pancreas 
during the anhepatic phase of the liver transplantation pro· 
cedure, and use of high-dose steroids for induction of im· 
munosuppression may contribute. Significant clinical pan-
creatitis is also more common in patients with active viral 
liver disease, particularly in patients with acute hepatitis B in 
the allograft. Z 
Aplastic Anemia 
Patients undergoing liver transplantation for non-A, non-~ 
hepatitis are at special risk of developing aplastic anemia. 1,5 
In a series of 32 patients with acute non-A, non-B hepatitis, 
9 patients developed aplastic anemia 1 to 7 weeks after trans-
plantation. Four of these died of infectious complications. 
Two patients followed for at least 1 year developed recovery 
of marrow function. 
Liver Biopsy Complications 
Liver biopsy is the most common procedure performed on 
patients after liver transplantation. Complications include 
pneumothorax, hemothorax, intraperitoneal hemorrhage, 
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intrahepatic or subcapsular hematoma, bacteremia, and 
, pseudoaneurysm of an intrahepatic artery or arteriobiliary fis-
tula with hematobilia. 
Infection 
Infections are the cause of most of the morbidity and mor-
tality after organ transplantation. Organisms that normally 
colonize the gastrointestinal tract and skin can become dan-
gerous pathogens in the immunosuppressed transplant recip-
ient. Modern immunosuppressive regimens are more selec-
tiv~ in their effects and have permitted less reliance on 
azathioprine and steroids. This has reduced the risk of bac-
terial infections and made them easier to manage, but 50% 
to 70% of organ recipients experience at least one bacterial 
infection. Latent viral infections often are present in other-
wise sterile tissues, and immunosuppression may permit viral 
replication with clinical infection, About 30% to 60% of pa-
tients experience a symptomatic viral infection. Herpes sim-
plex virus (HSV), CMV, Epstein-Barr virus \EBV), and VZV 
infections are the most frequently encountered. Invasive fun-
gal infections are also more common. 
EVALUATION OF FEVER 
Fever is always an important clinical finding in a transplant 
recipient. All fevers over 38.5°C must be thoroughly inves-
tigated. The basic evaluation includes liver function tests, a 
chest film, urinalysis, Gram stain of sputum, and cultures of 
blood, sputum. urine, and all drains, indwelling tubes, and 
lines. Viral cultures should be taken of buffv coat blood 
throat washes, and urine. An abdominal CT s'can usually i~ 
indicated. Additional studies to be considered include acute-
phase serum samples (including EBV, HSV, and CMV ti-
ters), arterial blood cultures for candidiasis. stool for ova and 
parasites. pelvic examination, head CT scan, skin tests for 
tuberculosis and mycoses, Legionella titers, spinal fluid ex-
amination, cholangiography, and hepatitis serology screens. 
Bronchoalveolar lavage and liver biopsy specimens should be 
stained and cultured for viruses and fungi when pneumonitis 
or hepatitis is suspected. 
VIRAL INFECTIONS 
Cytomegalovirus infections are the most common viral in-
fections encountered in patients after liver transplantation. In 
a review of 121 liver transplantations at the University of 
Pittsburgh, the overall incidence ofCMV infection was 59%, 
compared with 35% for HSV, 25% for EBV, and 7% for 
Vzv. III Symptomatic and disseminated CMV infections are 
more common in primary CMV infection than with reacti-
vation CMV infection. Infection may involve the urinary 
tract. gastrointestinal tract (esophagus, stomach, duodenum 
and small bowel, or colon), lungs, liver, and CNS. Trans-
mission from the organ donor is the most important source 
of primary CMV infection. Disseminated primary CMV in-
fection has been associated with prior treatment with mono-
clonal antibody but reactivation infection has not. 
There is e~idence that prophylactic high-dose acyclovir 
and intravenous immune globulin may be of value for CMV 
disease in transplant recipients. 145 High-dose acyclovir, 800 
mg orally four times a day, is begun as soon as the patient 
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has resumed oral intake. Patients are maintained on acyclovir 
for at least 6 months. Dosage should be adjusted for patients 
with impaired renal function, but doses of less than 800 
mgld are probably ineffective in preventing CMV infection. 
Patients who tend to have recurrent oral or genital herpes 
infections may be continued on acyclovir at a reduced dose 
(200 mg twice a day) beyond 6 months. High-risk patients, 
such as seronegative recipients who receive an organ from a 
seropositive donor, should also receive a course of CMV im-
mune globulin. 
HSV infections typically are limited to oral and genital 
herpes, but HSV may also produce pneumonitis or hepatitis. 
HSV hepatitis commonly occurs earlier (median, 18 days) 
than CMV hepatitis, which usually occurs 30 to 40 days after 
transplantation, and may be focal or diffuse in the liver. 78 
Symptomatic reactivation of HSV in seropositive patients is 
more common in those who have received therapy for rejec-
tion with monoclonal antibody. 113 Disseminated HSV infec-
tion has a poor prognosis, and early therapy with high-dose 
acyclovir is essential. Prophylactic acyclovir may be effective 
in preventing disseminated HSV disease. 
Exposure to VZV infection can have serious conse-
quences. Seronegative patients should receive VZV immune 
globulin (VZIG) within 72 hours of exposure to an infected 
person. In cases of strong exposure, such as to a family mem-
ber with chickenpox, it is advisable to give VZIG even to 
seropositive patients and to administer acyclovir to seronega-
tive patients, since clinical disease has occurred in susceptible 
people even after administration of VZIG. 95 Disseminated 
VZV requires high-dose acyclovir therapy. 
PNEUMOCYSTIS PNEUMONIA 
Pneumocystis pneumonia has long been one of the dreaded 
complications of immunosuppression in organ transplan-
tation patients. Oral prophylaxis with sulfamethoxazole-
trimethoprim (one single-strength tablet per day) is highly ef-
fective in preventing this infection. Patients who are unable 
to be treated with sulfamethoxazole-trimethoprim can be 
treated with dapsone, 100 mg/d, or aerosolized pentamidine, 
300 mg once a month. 61 Prophylaxis should be continued for 
life, but the frequency of sulfamethoxazole-trimethoprim can 
be reduced to three times per week. We have seen Pneumo-
cystis carinii pneumonia develop shortly after withdrawal of 
suppressive therapy in patients 3 or more years after trans-
plantation. Furthermore, suppressive prophylaxis may also 
afford protection from Legionella, Nocardia, and toxoplas-
mosis. 
FUNGAL INFECTIONS 
Candidal infections are common in immunosuppressed pa-
tients. Noninvasive overgrowth of oropharyngeal, esopha-
geal, and vaginal cavities is most common and can be man-
aged with topical therapy. Mycostatin suspension, 500,000 
IU (5 mL) every 6 hours, is given orally or through a naso-
gastric tube beginning after surgery and continued for several 
months until the dosage of immunosuppression is reduced. 
It should be reinstituted whenever immunosuppression is in-
creased, such as for treatment of rejection. Clotrimazole 
(Mycelex troche), which dissolves slowly in the mouth, can 
be used instead of mvcostatin. Candidal infections are more 
common and often more troublesome in patients with dia-
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betes. It is advisable to continue Candida prophylaxis longer 
and perhaps indefinitely in these patients. 
Invasive candidal infection requires treatment with sys-
temic therapy, such as amphotericin B or fluconazole. High-
risk patients should be considered for pretransplantation pro-
phylaxis to reduce Candida colonization of the gut. This 
may also be accomplished as part of a program of selective 
decolonization of the gut, which may reduce the incidence 
of gram-negative and candidal infections after transplanta-
tion. 5.164 We have used a combination of colistin, gentami-
cin, and nystatin or paste in Orabase (polymyxin 2%, gen-
tamicin 2%, and nystatin 2%) for patients waiting for 
transplantation in a critical care setting. 
Aspergillus infections may involve the lungs, upper respi-
ratory tract, skin, soft tissues, or CNS. The disease com-
monly presents as a diffuse pneumonia with patchy infiltrates 
rather than as a fungus ball in the lungs. Blood vessel inva-
sion with metastatic spread of infection occurs early. Devel-
opment of brain abscess is insidious and cure is difficult. De-
finitive diagnosis requires intracranial biopsy. A long course 
of systemic therapy with amphotericin B is indicated in pa-
tients with aspergillus infections. Flucytosine may benefit pa-
tients with ophthalmic or CNS involvement. Itraconazole, a 
new agent. has shown promise for the treatment of aspergil-
losis in our limited experience with it. 
Cryptococcal infections (lung, CNS, disseminated cuta-
neous infectioll) are another hazard in immunosuppressed 
patients. A spinal fluid examination with India ink stains and 
analysis for cryptococcal antigen should be considered in pa-
tients with persistent headache or signs of meningism and in 
all patients with pulmonary cryptococcal infection. 
Infections with Mucor or Rhizopus species are rare but 
may produce severe CNS or soft tissue infections that are 
difficult to eradicate. Treatment requires reduction of im-
munosuppression, local excision, and a long course of sys-
temic antifungal therapy. 
ANTITUBERCULAR PROPHYLAXIS 
Patients who are PPD-positive, especially those from areas 
with a high endemic rate of tuberculosis or those who travel 
to such areas, should receive antitubercular prophylaxis. Pa-
tients with a history of potential exposure and anergic skin 
reactivity should also be considered for prophylaxis with iso-
niazid (INH). INH prophylaxis usually is begun in the third 
week after liver transplantation and continued for at least 6 
months. 
EPSTEIN. BARR VIRUS AND 
LYMPHOPROUFERATIVE DISORDERS 
A ubiquitous DNA virus, EBV can produce a spectrum of 
syndromes in immunocompromised patients ranging from a 
typical mononucleosis syndrome to frank lymphoma. In ad-
dition to a classic mononucleosis presentation, the viral syn-
drome may be characterized by atypical findings such as jaw 
pain, arthralgias, joint space effusions, diarrhea, encephali-
tis, pneumonitis, mediastinal lymphadenopathy, ascites, and 
hepatitis. 123 Changes in the liver allograft in EBV infection 
range from findings typical of infectious mononucleosis to a 
distinctive histopathology characterized by a mixed mono-
nuclear and sinusoidal infiltrate, lobular hepatitis, and mild 
duct damage not in proportion to the severity of the inflam-
matory infiltrate. 
Lymphoproliferative disease is seen in patients with con-
genital and acquired immunodeficiency states, including 
transplantation patients receiving immunosuppressive medi-
cations. Most are associated with EBV infection. In some 
patients, EBV DNA cannot be found in tumor specimens. 166 
Also, EBV is trophic for B cells and about 15% of lympho-
mas are of T-cell origin. 109 In our experience, lymphomas 
after transplantation have occurred in 4.6% of combined 
heart and lung recipients, 2.2% of liver recipients, 1.8% of 
heart recipients, and 1 % of kidney recipients. 100 The higher 
incidence in extrarenal transplant recipients may be related 
to the higher levels of immunosuppression used in patients 
for whom there is no alternative artificial organ support if 
therapy for graft rescue fails. 
Posttransplantation lymphomas are believed to be a con-
sequence of overall levels of immunosuppression rather than 
treatment with any particular agent. The disease may present 
as a diffuse involvement of multiple organ systems with mas-
sive infiltration of many tissues with immunoblasts or mature 
plasma cells or as solid tumors that involve the tonsils, lungs, 
and spleen with spread to the liver, kidneys, lymph nodes. 
and brain. Most patients who survive this complication have 
evidence of primary or reactivated EBV infection, polYclonal 
lesions. solid tumors rather than diffuse disease, and B-cell 
hyperplasia rather than lymphoma. In liver recipients, the 
hepatic allograft is involved in one third of cases, and tonsils, 
kidneys, and small bowel often are involved. 21 
Early recognition, reduction, or withdrawal of immuno-
suppression and systemic antiviral therapy with acyclovir or 
ganciclovir are important for successful management of these 
lesions. Localized solid lesions in the gastrointestinal tract 
may obstruct or perforate and should be resected. a-Inter-
feron has been used in an effort to prevent early lymphoma 
transformation. 79 Anti-CD2I-specific and anti-CD24-spe-
cific (anti-B-cell) monoclonal antibodies have recently been 
shown to be effective in controlling diffuse, severe oligoclonal 
B-cell lymphoproliferative disease in patients without CNS 
involvement. 39 Sometimes more aggressive monoclonallym-
phomas require conventional anticancer therapy. 
Immunosuppression 
Recent improvements in immunosuppression have been re-
sponsible for much of the success now being experienced in 
solid organ transplantation. We can expect further significant 
advances in the near future as another generation of agents 
is introduced into clinical practice. This section briefly re-
views the immunosuppressive agents currently in use and the 
management strategies for induction immunosuppression 
and treatment of rejection. 
CYCLOSPORINE 
Cyclosporine was isolated from a fungus found growing in a 
soil sample taken from the largest highland plateau in Eu-
rope, the Hardanger Valda in southern Norway. Borel first 
described the immunosuppressive properties of cyclosporine 
in 1976, and clinical trials were begun by CaIne in 1978. 
The systematic use of cyclosporine in combination with low-
dose prednisone was begun by Starzl in 1980. The improved 
survival achieved by Starzl in his first trials with the drug in 
liver transplant recipients demonstrated that liver transplan-
tation was a practical therapy for patients with end-stage liver 
A National Institutes of Health Consensus Devel-
conference held in 1983 supported this conclusion. 
Health Care Financing Administration now provides 
Medicare reimbursement for some of the most common in-
. dications for pediatric and adult liver transplantation. 
Cyclosporine is a highly lipid-soluble drug, and its ab-
. sorption depends on the enterohepatic circulation. It is 
. '. metabolized in the liver, and the major route of excretion is 
in bile. Toxicity is most commonly manifested by hyperten-
sion, tremulousness, gingival hyperplasia, and nephrotoxic-
ity. Acute nephrotoxicity is characterized by hyperkalemic re-
.' nal tubular acidosis and chronic cyclosporine nephrotoxicity, 
•... by a progressive interstitial fibrosis of the kidneys. A low se-
.. rum magnesium level potentiates neurotoxicity, and this may 
result in seizures, especially when cyclosporine is adminis-
tered intravenously. Cyclosporine can produce changes in 
personality, including paranoid delusions and hallucinations. 
Liver function may also be impaired by cyclosporine, but this 
is much less common than nephrotoxicity and other causes 
of liver dysfunction (rejection, hepatitis, technical compli-
cations) must be ruled out. 
Cyclosporine initially is administered intravenously as a 
continuous infusion. usually at a dose of 3 to 5 mg/kgJd. As 
soon as patients are able to tolerate oral intake, oral cyclo-
sporine. 12 to 15 mg/kgJd in two divided doses, is begun. 
Daily trough levels of serum or whole blood are monitored 
and levels adjusted to maintain an appropriate therapeutic 
" range. Once oral dosage is well established and blood levels 
are stable, patients are weaned off the intravenous form. 
Because of concern about the nephrotoxicity of cyclo-
sporine, various cyclosporine-sparing protocols have been 
adopted by transplant centers during the induction phase of 
.c immunosuppression. In this approach, no cyclosporine is 
~I: given during the first 2 to 7 days after transplantation until 
good urine output and creatinine clearance are demon-
:'1 
strated, During the period of cyclosporine sparing, patients 
may be treated with various combinations of azathioprine, 
prednisone, and either polyclonal or monoclonal antibody. 
Once good renal function is established, oral cyclosporine is 
started. 
Drugs that affect hepatic enzyme systems, especially the 
cytochrome P-450 system, can alter the metabolism of cyclo-
sporine. Two of the more common drugs that do this are 
phenytoin (Dilantin), which causes a fall in cyclosporine se-
rum concentration, and erythromycin, which causes signifi-
cant increases and may precipitate acute toxicity. These drugs 
must be used with caution and with careful attention to the 
monitoring of blood levels. 
CORTICOSTEROIDS 
Although cyclosporine has permitted a significant reduction 
~D in the amounts of steroid required to maintain a liver allo-
~K graft, corticosteroids still have an important role in the in-
~ duction and maintenance of immunosuppression in liver 
transplant recipients. At most centers, patients receive a I-g t· bolus of methylprednisolone during surgery followed by a 
.. high-dose taper of steroids until a daily maintenance dose of 
1",. 20 mg is reached (less in young children). In patients with 
i diabetes, advanced osteoporosis, or refractory hypertension, 
~ an attempt usually is made to lower the dose of steroids fur-
:: . ther early in the course, but this is not always possible. Ste-
I.. 
'. ......... raids are also important in the management of acute rejec-
'. tion. The lower maintenance doses of steroids able to be used 
, 
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in combination with cyclosporine allows pediatric patients to 
resume normal growth and development after liver transplan-
tation. 159 
AZATHIOPRINE 
Azathioprine is widely used in transplantation to spare cyclo-
sporine during the early recovery phase when renal function 
may be compromised, to provide an adjunctive agent in pa-
tients unable to tolerate usual doses of cyclosporine, or to 
augment immunosuppression in patients with persistent or 
recurrent rejection despite appropriate therapy with cyclo-
sporine and steroids. Therapy usually is started at 1 mglkg 
and may be gradually increased to 1.5 to 2 mglkg as needed. 
If the peripheral leukocyte count falls below 5000/f..LL, the 
dose is reduced. If the count falls below 3000/f..LL, the drug 
is discontinued. 
ANTIBODY THERAPY 
Muromonab-CD3 (Orthoclone OKT3) is a mouse antihu-
man monoclonal antibody with activity against the CD3 de-
terminant on human T cells. A highly effective immunosup-
pressive agent, it is used for induction immunosuppression 
as part of cyclosporine-sparing protocols; for induction im-
munoprophylaxis, especially in high-risk patients (patients 
with high titers of cytotoxic antibody or patients with a history 
of graft rejection); and for the treatment of steroid-resistant 
allograft rejection. 23,48.98 A recent report could find no long-
term benefit to the routine use of prophylactic OKT3 and 
recommended that OKT3 be reserved for the treatment of 
steroid-resistant rejection and for cyclosporine intolerance. 93 
OKT3 usually is administered as a 5-mL intravenous bolus 
over 5 minutes repeated daily for 10 to 14 days. Fluid over-
load should be corrected before OKT3 is given. Patients 
should be premedicated with steroids, antihistamine, and 
acetaminophen for the first few doses. Adverse effects such as 
headache, joint pains, fever, chills, tachycardia, nausea, and 
abdominal discomfort are common and probably a result of 
the sudden lysis of lymphocytes and release of cytokines with 
the first few administrations. Seizures mav occur after admin-
istration and are potentiated by hypocalcemia or hyponatre-
mia. Aseptic meningitis has been reported in less than 5% of 
patients. It causes fever and headache, and some patients ex-
perience nuchal rigidity and altered mentation. Polymorpho-
nuclear leukocytes and lymphocytes may be present in spinal 
fluid, but spinal fluid cultures are negative. The syndrome is 
self-limited and does not require the drug to be stopped. 
Other monoclonal agents directed against T-cell determi-
nants and interleukin receptors are under investigation, but 
OKT3 is the only Food and Drug Administration-approved 
monoclonal antibody in use. Because OKT3 is a mouse pro-
tein, patients may develop antimurine antibodies that inac-
tivate the drug. Most patients develop only low titers of an-
timurine antibody with a first course of treatment, and this 
titer decreases with time. Thus, many patients can be re-
treated with a second course of OKT3 if rejection recurs. It 
often is helpful to monitor CD3 cell counts and OKT3 levels 
in patients being retreated with OKT3, especially if there is a 
poor clinical response. The drug is ineffective if CD3 cell 
counts do not drop or effective serum levels cannot be 
achieved. 22.38.130 
Now that monoclonal therapy is available, there is much 
less use of polyclona1 agents. These preparations are still used 
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by some centers for cyclosporine-sparing during induction 
and as an alternative therapy to the monoclonal agents in 
patients with recurrent rejection or a poor response to OKT3. 
FK 506 AND OTHER NEW AGENTS 
FK 506 represents the first of a new generation of immuno-
suppressive agents. It is a macrolide antibiotic belonging to 
the same family of compounds as erythromycin and a potent 
immunosuppressive agent. Its actions on T cells are similar 
to those of cyclosporine, including suppression of interleu-
kin-2 production, but it is many times more potent and acts 
on a different cell receptor. 55,\ 12 In extensive clinical trials at 
the University of Pittsburgh, FK 506 has been found to be 
remarkably effective in preventing and controlling liver allo-
graft rejection. and many patients can be weaned off steroids 
early in their course after transplantation. 150 Most patients 
who develop steroid-resistant rejection during therapy with 
FK 506 can be treated with a short, 3- to 5-day course of 
OKT3. FK 506 has also proved to be a highly effective rescue 
drug for patients who cannot be maintained on cyclosporine 
and those with failing grafts despite aggressive cyclosporine 
therapy. -11 The drug is more effective than any other available 
agent in reversing or decelerating the progression of chronic 
allograft rejection and in preventing acute vanishing bile duct 
sYndrome. 
. The toxicity profile of FK 506 differs from that of cyclo-
sporine. It is less nephrotoxic, and troublesome hypertension 
is less common. Gastrointestinal adverse effects, especially 
nausea and diarrhea, are common early complaints and may 
be related to an antibiotic action of the drug in the gut. Head-
ache and insomnia are common complaints and are dose-
related. Tremors are much less common than with cyclo-
sporine, and the drug may cause mild hair loss rather 'than 
the hirsutism commonly experienced by patients on cyclo-
sporine. The severest neurologic complications seen with FK 
506 are seizures and central pontine myelinolysis with severe 
speech and motor disturbances. As with cyclosporine, these 
complications are most common early after transplantation, 
when the drug is being given intravenously. Metabolic dis-
turbances, especially significant fluctuations in serum so-
dium levels, have also been associated with such neurologic 
disorders in transplant recipients. 10.35.167 
When FK 506 is given, much of it is cleared on the first 
pass through the liver. Therefore. graft function has a signif-
icant effect on drug activity and blood levels. 69 In the early 
period after transplantation, FK 506 levels may rise rapidly 
to toxic levels if graft function is poor. Appropriate monitor-
ing of blood levels and adjustments in dosage must be made 
during periods of graft dysfunction. 
In addition to its impressive immunosuppressive effects, 
FK 506 has a remarkable hepatotrophic effect that is stronger 
than that seen with cyclosporine. In an experimental animal 
model in which portal blood supply is diverted by an Eck 
fistula to the vena cava and FK 506 is selectively infused into 
one lobe of the liver, the size, anatomic quality, and repli-
cation ofhepatocytes is enhanced in the FK 506-infused por-
tion of the liver. 138 This effect of FK 506 on hepatic regen-
eration and repair may make it particularly advantageous for 
use in liver transplantation. 
Several other interesting agents are under investigation 
and may become important for clinical practice in the near 
future. Among these are rapamycin, an antibiotic with some 
similarities to FK 506, and RS-61143, a guanine monophos-
phate inhibitor. 
Allograft Rejection 
Antibody-mediated hyperacute rejection of the liver has been 
demonstrated in animal models but is rare in the clinical set-
ting. In kidney transplantation, hyperacute rejection usually 
occurs on the operating table because antibody deposition 
and accumulation of formed blood elements rapidly destroy 
the microcirculation of the kidney. In the case of a liver graft, 
the process may evolve over 24 to 48 hours after surgery and 
after a brief initial period of good graft function. It is most 
likely to occur in patients in whom an ABO incompatibility 
between donor and recipient has been crossed and occasion-
ally occurs in a patient with a strongly positive antibody cross-
match. Hyperacute rejection usually is characterized by a se-
vere hemorrhagic necrosis of the liver within hours or days 
of implantation. Submassive necrosis with a sparse polymor-
phonuclear infiltrate in the portal tracts and hepatic lobules 
has also been described in a patient with a high titer of Ivrn-
phocytotoxic antibody.9 Patchy deposits of immunoglobulin, 
C3 complement component, factor P, and fibrinogen are 
characteristic. 52 Accelerated acute cellular rejection can also 
occur in the first few days after transplantation. Liver biopsy 
is necessary to distinguish between early forms of rejection 
and ischemic graft injury. 
Acute cellular rejection may occur at any time after liver 
transplantation and may be characterized by any or all of the 
following: malaise, fever. graft tenderness or enlargement, 
and diminished graft function with elevated levels of biliru-
bin and aminotransferase or canalicular enzymes. The pres-
ence of preformed antidonor lymphocytotoxic antibody is not 
predictive of hyperacute rejection but may be an important 
warning that the recipient is more likely to experience acute 
cellular rejection and that rejection may be more difficult to 
treat. 
Acute cellular rejection is characterized by a portal infil-
trate with damage to small bile ducts in the portal tracts. In-
flammatory cells may also accumulate beneath the portal and 
terminal hepatic veins (central venulitis). An inflammatory 
arteritis may also be present, but the vessels involved typically 
are in the hilum and not accessible by liver biopsy. The he-
patic lobule usually is spared, but in severe rejection, the 
inflammatory infiltrate may spill over into the hepatic lobule 
and be associated with hepatic necrosis. The histologic pic-
ture is different from the piecemeal necrosis seen with hepa-
titis. 
Chronic rejection is an obliterative arteriopathy that re-
sults in an insidious and relentless loss of small bile ducts. It 
typically presents with elevated levels of canalicular enzymes 
and progressive jaundice. Hepatic synthetic function usually 
is well preserved, and most patients feel well until late in the 
course. In some cases, chronic rejection may progress rapidly, 
a syndrome that has been called the acute vanishing bile duct 
syndrome. Vanishing bile duct syndrome may be more com-
monly seen in patients with a positive lymphocytotoxic anti-
body crossmatch. 6 The syndrome has also been reported to 
be less frequent in patients treated with combination immu-
nosuppressive regimens, such as triple therapy with cyclo-
sporine, prednisone, and azathioprine or quadruple regimens 
including these agents and prophylactic antibody ther-
apy.1l3·160 Hepatic lobular changes of chronic rejection also 
. reflect progressive ischemic damage and include centrolobu-
lar cholestasis, patchy acidophilic necrosis, centrolobular 
ballooning or atrophy of hepatocytes, perivenular sclerosis, 
and intrasinusoidal foam cells. 
.' The differential diagnosis of allograft rejection commonly 
includes preservation injury, vascular compromise, biliary 
tract obstruction, viral or toxic hepatitis, systemic infection, 
and recurrent disease. Liver biopsy usually is required for de-
finitive diagnosis, but Doppler ultrasonography, cholangiog-
raphy, angiography, and CT scanning may be needed as well, 
depending on the clinical setting. Serologic screens for hep-
atitis and other infectious disease evaluations may also be re-
quired. 
MANAGEMENT OF REJECTION 
No effective therapy exists for hyperacute rejection of the 
liver other than urgent retransplantation of the liver. Acute 
cellular rejection usuallv is treated with steroids and. if there 
is an inadequate response, a course of antibody therapy. In 
cases of chronic rejection in which bile ducts are still present 
in some portal tracts on liver biopsy, conversion from cvclo-
sporine to FK 506 may rescue the graft or significantly slow 
the progression of the rejection process. Otherwise, chronic 
rejection is refractorv to further therapy. The inevitability of 
retransplantation should be accepted, and overtreatrnent of 
the patient should be avoided. 
Tuning of Transplantation 
Outcome is related to patient condition at the time of trans-
plantation. Liver grafts are allocated in the United States ac-
cording to a point system that is based mainly on medical 
urgencv, as defined by the required level of medical care, 
and waiting time. Patients with the highest urgency and 
longest waiting times receive the highest priority. Experience 
shows, however, that these patients also have the highest 
mortality after liver transplantation. Patients in the lowest ur-
gencv classes have 6-month survival rates approaching 90%, 
whereas those who go to the operating room from an inten-
sive care unit to receive a liver transplant have only a 65% 
chance of survival. 45 
Liver transplantation is not experimental, and it is now 
widely available in North America, Europe, and Australia. 
It is not an option to be considered only for a patient with 
end-stage liver disease who has reached a desperate or debil-
itated state. Excellent results can be achieved if patients are 
referred before their condition deteriorates to the point at 
which survival is jeopardized. The severely ill deserve to be 
and can be served, but early referral is essential to further 
reduce morbidity, mortality, and cost. 
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